Reviewed 10 November 2026 for medical education. This material is not a prescribing protocol; apply local clinical guidance and individual assessment.
Introduction and learning objectives
Beta-lactams inhibit bacterial cell-wall synthesis and are foundational to treating susceptible bacterial infections. Choosing among them requires understanding penicillin-binding proteins (PBPs), beta-lactamases, time-dependent killing, site of infection, allergy history, local susceptibility and organ function [1,2].
Classification
- Penicillins: penicillin G/V; aminopenicillins amoxicillin/ampicillin; antistaphylococcal oxacillin/nafcillin; antipseudomonal piperacillin.
- Cephalosporins: cefazolin, cefuroxime, ceftriaxone, cefepime, ceftaroline and newer agents. ‘Generation’ is only a rough guide; ceftaroline has MRSA activity whereas ceftriaxone does not.
- Carbapenems: meropenem, imipenem-cilastatin and ertapenem; ertapenem lacks reliable Pseudomonas or Acinetobacter activity.
- Monobactams: aztreonam, primarily active against aerobic Gram-negative organisms.
- Beta-lactamase inhibitor combinations: amoxicillin-clavulanate, piperacillin-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, ceftolozane-tazobactam and aztreonam-avibactam; inhibitory spectra differ markedly [1,2].
Mechanism, pharmacodynamics and resistance
The beta-lactam ring acylates PBPs, inhibiting transpeptidation of peptidoglycan and promoting bacterial death. The principal PK/PD index is the fraction of the dosing interval that free-drug concentrations exceed the organism MIC (fT>MIC); prolonged infusion can improve target attainment for selected severe infections. Resistance includes enzyme-mediated hydrolysis (ESBL, AmpC and carbapenemases), altered PBPs, permeability defects and efflux. Metallo-beta-lactamases such as NDM hydrolyze most beta-lactams but not aztreonam; aztreonam may still require protection against coproduced serine beta-lactamases [1,2].
Clinical applications
Penicillin remains important for susceptible streptococcal disease and syphilis; cefazolin for susceptible MSSA infections; ceftriaxone for selected community-onset infections; antipseudomonal agents for susceptible Pseudomonas disease. Suspected meningitis, endocarditis and sepsis demand syndrome-specific regimens, timely cultures and source control. IDSA 2026 AMR guidance favors organism- and mechanism-specific selections for ESBL producers, CRE and difficult-to-treat resistant Pseudomonas rather than assuming all novel inhibitor combinations are interchangeable [2].
Pharmacokinetics and dosing
Many beta-lactams are largely eliminated by kidneys; dose adjustments and augmented-renal-clearance assessment matter in critical illness. Ceftriaxone has mixed biliary/renal elimination; nafcillin and oxacillin differ from renally cleared penicillins. Imipenem is combined with cilastatin to prevent renal metabolism. Encephalopathy or seizures can occur with excessive exposure, especially with cefepime and impaired renal function [1].
Adverse effects, allergies and interactions
Common adverse effects include rash, diarrhea and C. difficile infection. Immediate IgE-mediated allergy, severe cutaneous adverse reactions and nonallergic adverse effects must be distinguished. A remote unverified penicillin-allergy label should be assessed rather than automatically excluding all beta-lactams; side-chain similarity helps estimate cross-reactivity. Monitor renal function and blood counts during prolonged therapy when indicated. Certain beta-lactams interact with valproate (especially carbapenems, which can markedly reduce valproate concentrations) [1].
Clinical perspective
Obtain susceptibility information where possible, use an effective narrow agent once microbiology returns, and individualize duration and route. Novel spectrum does not imply superiority for routine infections [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Infectious Diseases Society of America. IDSA 2026 guidance on the treatment of antimicrobial resistant Gram-negative infections. Published 2026 Jul 30. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.